M
Michael Keoni Manion
Researcher at Wilmington University
Publications - 39
Citations - 625
Michael Keoni Manion is an academic researcher from Wilmington University. The author has contributed to research in topics: Cytotoxic T cell & Generator (computer programming). The author has an hindex of 9, co-authored 39 publications receiving 609 citations. Previous affiliations of Michael Keoni Manion include Fred Hutchinson Cancer Research Center.
Papers
More filters
Book ChapterDOI
Mitochondria and apoptosis: new therapeutic targets.
David M. Hockenbery,Christopher D. Giedt,Jason W. O'Neill,Michael Keoni Manion,Deborah E. Banker +4 more
Journal ArticleDOI
BCL-XL dimerization by three-dimensional domain swapping.
TL;DR: BCL-X(L) 3D DS dimers have increased pore-forming activity compared to monomers, suggesting that 3DDS dimers may act as intermediates in membrane pore formation.
Journal ArticleDOI
Targeting BCL-2-related proteins in cancer therapy.
TL;DR: Initial efforts have been centered on disrupting protein-protein interactions within the BCL-2 homology (BH) family, and substantial progress has been made using molecular modeling and drug leads.
Journal ArticleDOI
Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy.
TL;DR: A substantial number of small molecules that bind to BCL-2 or BCL -XL are now available for pre-clinical testing; in turn, basic studies with these reagents should yield new insights about optimal strategies to disrupt B CL-2 survival functions.
Journal ArticleDOI
Bcl-XL Mutations Suppress Cellular Sensitivity to Antimycin A
Michael Keoni Manion,Jason W. O'Neill,Chris D. Giedt,Kristine M. Kim,Kam Y.Z. Zhang,David M. Hockenbery +5 more
TL;DR: The results indicate that BCL-XL is a principal target mediating AA cytotoxicity, with normal cellular anti-apoptotic function but suppressed sensitivity to AA.